Department of Endocrinology, Bellvitge University Hospital, Carrer de la Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Pathology, Bellvitge University Hospital, Carrer de la Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
Rev Endocr Metab Disord. 2019 Jun;20(2):219-238. doi: 10.1007/s11154-019-09484-1.
In 2017, the World Health Organization established that pituicytoma, granular cell tumor (GCT), spindle cell oncocytoma (SCO) and sellar ependymomas (SE) are posterior pituitary tumors (PPT). They probably arise from the pituicytes and may constitute a unique histopathological entity. We carried out a systematic review using PubMed's database. A total of 266 patients with pathological diagnosis of PPT (135 pituicytomas, 69 GCT, 47 SCO, 8 SE and 7 mixed histology tumors) were analyzed. Gender distribution was identical and median age at diagnosis was 48 ± 21.8 years. Main presentation symptoms were visual disorders (n = 142; 58.1%), headache (n = 99; 40.5%), hypopituitarism (n = 84; 34.4%), hypercortisolism (n = 10; 4.1%), polyuriapolydipsia (n = 6; 2.4%) and acromegaly features (n = 5; 2.0%). On MRI, 122 (47.6%) patients showed sellar with suprasellar extension masses, 67 (23.1%) were suprasellar and 63 (24.6%) exclusively sellar. Median tumor size was 22.0 ± 14.2 mm. Two hundred sixty four patients underwent surgery, transphenoidal access was selected in 132 (64.4%) and craniotomy in 58 (28.3%). Complications were hypopituitarism (n = 70; 42.1%), diabetes insipidus (n = 55; 33.1%) and hemorrhage (n = 50; 30.1%). Tumor persisted in 93 patients (45.6%) and recurred in 13 (6.4%). Regarding comparison between main types of PPT, SCO patients were diagnosed later (60.0 vs 47.0 vs 47.0 years, p = 0.023), the tumor was larger 25.0 mm [10.8] vs 20.0 mm [14.2] vs 2.0 mm [15.0] and they were frequently sellar with suprasellar extension tumors (71.7% vs 46.2% vs 32.8%, p = 0.003) compared to pituicytoma and GCT. In conclusion, PPT are rare tumors and have been misdiagnosed mainly as non-functioning pituitary adenomas. Different types of PPT share similar epidemiology, clinical manifestations and surgical outcomes. Surgery is the only curative option but complications and subtotal resection are common.
2017 年,世界卫生组织将垂体细胞瘤、颗粒细胞瘤(GCT)、梭形细胞嗜酸细胞瘤(SCO)和鞍内室管膜瘤(SE)定义为垂体后叶肿瘤(PPT)。它们可能起源于垂体细胞,可能构成一种独特的组织病理学实体。我们使用 PubMed 数据库进行了系统综述。共分析了 266 例经病理诊断为 PPT 的患者(135 例垂体细胞瘤、69 例 GCT、47 例 SCO、8 例 SE 和 7 例混合组织学肿瘤)。性别分布相同,中位诊断年龄为 48±21.8 岁。主要表现症状为视力障碍(n=142;58.1%)、头痛(n=99;40.5%)、垂体功能减退(n=84;34.4%)、皮质醇增多症(n=10;4.1%)、多尿多饮(n=6;2.4%)和肢端肥大症特征(n=5;2.0%)。在 MRI 上,122 例(47.6%)患者显示鞍内伴鞍上延伸肿块,67 例(23.1%)为鞍上,63 例(24.6%)仅为鞍内。肿瘤大小中位数为 22.0±14.2mm。264 例患者接受了手术治疗,经蝶窦入路 132 例(64.4%),开颅手术 58 例(28.3%)。术后并发症为垂体功能减退(n=70;42.1%)、尿崩症(n=55;33.1%)和出血(n=50;30.1%)。93 例患者(45.6%)肿瘤残留,13 例(6.4%)肿瘤复发。主要 PPT 类型之间的比较,SCO 患者的诊断年龄较晚(60.0 岁 vs 47.0 岁 vs 47.0 岁,p=0.023),肿瘤较大 25.0mm[10.8] vs 20.0mm[14.2] vs 2.0mm[15.0],且常为鞍内伴鞍上延伸肿瘤(71.7% vs 46.2% vs 32.8%,p=0.003),与垂体细胞瘤和 GCT 相比。总之,PPT 是罕见肿瘤,主要被误诊为无功能垂体腺瘤。不同类型的 PPT 具有相似的流行病学、临床表现和手术结果。手术是唯一的治愈方法,但并发症和次全切除很常见。